Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Medtronic
McKinsey
Colorcon

Last Updated: May 26, 2022

NYMALIZE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Nymalize patents expire, and when can generic versions of Nymalize launch?

Nymalize is a drug marketed by Azurity and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in NYMALIZE is nimodipine. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the nimodipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nymalize

A generic version of NYMALIZE was approved as nimodipine by HERITAGE PHARMS on May 2nd, 2007.

  Sign up for a Free Trial

Summary for NYMALIZE
Drug patent expirations by year for NYMALIZE
Drug Prices for NYMALIZE

See drug prices for NYMALIZE

Recent Clinical Trials for NYMALIZE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Johns Hopkins UniversityEarly Phase 1

See all NYMALIZE clinical trials

Paragraph IV (Patent) Challenges for NYMALIZE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NYMALIZE Oral Solution nimodipine 6 mg/mL 203340 1 2021-11-29

US Patents and Regulatory Information for NYMALIZE

NYMALIZE is protected by five US patents.

Patents protecting NYMALIZE

Non-aqueous liquid nimodipine compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS

Non-aqueous liquid nimodipine compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS

Non-aqueous liquid nimodipine compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS

Dispenser for medicaments and method and apparatus for making same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dispenser for medicaments and method and apparatus for making same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity NYMALIZE nimodipine SOLUTION;ORAL 203340-001 May 10, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Azurity NYMALIZE nimodipine SOLUTION;ORAL 203340-002 Apr 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Azurity NYMALIZE nimodipine SOLUTION;ORAL 203340-002 Apr 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
Baxter
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.